PMEF
PRLD icon

Point72 Middle East FZE’s Prelude Therapeutics PRLD Stock Holding History

Point72 Middle East FZE’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,680
Closed -$9.58K – 1974
2023
Q1 		$9.58K Buy
+1,680
New +$10.2K ﹤0.01% 1487

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Point72 Middle East FZE's PRLD Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Prelude Therapeutics (PRLD) in Q2 2023, closing a stake of 1,680 shares — an estimated $9.58K sold.

Point72 Middle East FZE first reported a position in PRLD in Q1 2023 and held it in 1 quarter. The position peaked at $9.58K in Q1 2023. 55 funds tracked by Wall St. Rank hold PRLD as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Prelude Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,680 Prelude Therapeutics shares in Q2 2023, an estimated $9.58K.
  • Point72 Middle East FZE first reported a position in Prelude Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Prelude Therapeutics position peaked at $9.58K in Q1 2023.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.